Drug Database · Clinicians

Amino acids + Glucose + Lipids

Brands (3) Nutriflex Lipid Peri, Nutriflex Lipid Special, Nutriflex Omega PeriShow all

Part of: Parenteral nutrition products (Drug Index, by product type)

Parenteral nutrition PH FDA category
Fixed-dose combination.

Rx · Prescription drug3 PH products PN kidney notes reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Component information

No US or EU label exists for this exact combination, so information is shown for each component.

Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney dosing for each component (single-agent) is shown under Component information.

Kidney-specific guidance from renalcarematters.com: in preparation.

Parenteral nutrition: kidney notes

Brand-specific kidney notes for the parenteral nutrition products filed under this generic: composition from the manufacturer SmPC or package insert, its kidney-related text, and how the product fits the guideline. Sources are listed under References.

Brands: Nutriflex Lipid Peri · Nutriflex Lipid Special · Nutriflex Omega Peri

Kidney notes: Nutriflex Lipid Peri

Nutriflex Lipid Peri (B. Braun Melsungen AG) is a lower-osmolarity three-chamber bag of amino acids with electrolytes, glucose and a lipid emulsion for peripheral infusion. Philippine registrations: 1250, 1875 and 2500 ml bags. It is a standard formula containing potassium and phosphate.

Composition

Per presentation1250 ml bag1875 ml bag2500 ml bag
Amino acids (g)406080
Nitrogen (g)5.78.611.4
Lipid (g)5075100
Carbohydrate (glucose) (g)80120160
Energy, total (kcal)95514351910
Energy, non-protein (kcal)79511951590
Sodium (mmol)5075100
Potassium (mmol)304560
Magnesium (mmol)34.56
Calcium (mmol)34.56
Phosphate (mmol)7.511.2515
Zinc (mmol)0.030.0450.06
Chloride (mmol)487296
Acetate (mmol)406080
  • Theoretical osmolarity 840 mOsm/l; osmolality 950 mOsm/kg (SmPC).
  • Composition from the Irish (EU) SmPC of NuTRIflex Lipid peri; the Philippine package insert was not available to compare.

Composition from the cited manufacturer SmPC/package insert; values independently re-checked November 17, 2026.

Dose and rate limits

  • Adults and adolescents from 14 years: maximum daily dose 40 ml/kg body weight; maximum infusion rate 2.5 ml/kg/hour (SmPC 4.2).

Kidney notes

  • Contraindicated in "severe renal insufficiency in absence of renal replacement therapy" and in disturbances of the electrolyte and fluid balance (SmPC 4.3).
  • Give with caution to patients with impaired cardiac or renal function; experience in renal failure is limited (SmPC 4.4).
  • Check serum electrolytes, water balance, acid-base balance and renal function; take care when giving other solutions that contain phosphate, zinc, magnesium or calcium (SmPC 4.4).

How it fits the ESPEN 2021 kidney nutrition guideline

  • ESPEN 2021 Recommendation 18 (Grade of recommendation 0 – Consensus (82.6% agreement)): protein intakes that may be prescribed are 0.6–0.8 g/kg body weight (BW)/d for a hospitalized patient with CKD without acute/critical illness; 1.2 g/kg BW/d with CKD and KF on conventional intermittent chronic KRT without acute/critical illness; 0.8–1.0 g/kg BW/d with AKI or AKI on CKD without acute/critical illness; start with 1 g/kg BW/day and gradually increase up to 1.3 g/kg BW/d if tolerated with acute/critical illness not on KRT; 1.3–1.5 g/kg/d for critically ill patients on conventional intermittent KRT; and 1.5 g/kg/d up to 1.7 g/kg/d for critically ill patients on continuous KRT (CKRT) or prolonged intermittent KRT (PIKRT). "If available, the pre-hospitalization body weight or usual body weight may be preferred over the ideal BW. Actual BW should not be considered for a protein prescription." (AKI, acute kidney injury.)
  • ESPEN 2021 Recommendation 25: "The choice of the most appropriate EN or PN formula should be made based on the calorie and protein ratio to provide the most accurate dosing in clinical practice." Grade of recommendation B – Strong consensus (91.3% agreement). (PN, parenteral nutrition.)
  • ESPEN 2021 Recommendation 24: "No disease-specific enteral nor parenteral formula oriented for patients with reduced kidney function should be routinely utilized in every patient with AKI, AKI on CKD, or CKD with KF in comparison to conventional formulas. Instead, their use is to be individualized (see recommendation 26)." Grade of recommendation B – Consensus (87.5% agreement).
  • ESPEN 2021 Recommendation 26: "In selected patients with electrolyte and fluid imbalances, concentrated “renal” EN or PN formulas with lower electrolyte content may be preferred over standard formulas." Grade of recommendation GPP – Strong consensus (95.7% agreement). (GPP, good practice point.)
  • ESPEN 2021 Recommendation 31: "Electrolytes abnormalities are common in patients with AKI, AKI on CKD, or CKD with KF receiving KRT and shall be closely monitored." Grade of recommendation A – Strong consensus (100% agreement).
  • ESPEN 2021 Recommendation 29: "Serum glucose levels shall be maintained between 140–180 mg/dl in hospitalized patients with AKI, AKI on CKD, or CKD with KF." Grade of recommendation A – Strong consensus (95.5% agreement). Recommendation 30: "Tight glucose control (80–110 mg/dl) shall not be pursued because of the increased risk of hypoglycemia." Grade of recommendation A – Strong consensus (100% agreement).
  • ESPEN 2021 Recommendation 14: "For patients undergoing KRT, the total energy provision by additional calories given in the form of citrate, lactate, and glucose from dialysis/hemofiltration solutions should be included in the calculations to determine the total daily energy provision to avoid overfeeding." Grade of recommendation B – Strong consensus (100% agreement). (KRT, kidney replacement therapy.)
  • ESPEN 2021 Recommendation 4: "Intradialytic parenteral nutrition (IDPN) shall be applied in malnourished non-critically ill hospitalized patients with CKD and KF on hemodialysis, or the same patients if at risk of malnutrition that fail to respond or do not tolerate ONS or EN." Grade of recommendation A – Strong consensus (91.7% agreement). (CKD, chronic kidney disease; KF, kidney failure; ONS, oral nutritional supplements; EN, enteral nutrition.)

Bottom line

A standard peripheral three-chamber bag. In severe renal insufficiency it needs renal replacement therapy; count its potassium and phosphate and its volume, and monitor electrolytes and renal function.

renalcarematters.com notes, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Check the current Philippine package insert before use. renalcarematters.com, reviewed

Kidney notes: Nutriflex Lipid Special

Nutriflex Lipid Special (B. Braun Melsungen AG) is a high-concentration three-chamber bag of amino acids with electrolytes, glucose and a lipid emulsion for parenteral nutrition. Philippine registrations: 625, 1250, 1875 and 2500 ml bags. It is a standard formula, higher in protein per ml, containing potassium and phosphate.

Composition

Per presentation625 ml bag1250 ml bag1875 ml bag2500 ml bag
Amino acids (g)35.971.8107.7143.6
Nitrogen (g)5101520
Lipid (g)255075100
Carbohydrate (glucose) (g)90180270360
Energy, total (kcal)740147522152950
Energy, non-protein (kcal)600119517952390
Sodium (mmol)33.567100.5134
Potassium (mmol)23.54770.594
Magnesium (mmol)2.655.37.9510.6
Calcium (mmol)2.655.37.9510.6
Phosphate (mmol)10203040
Zinc (mmol)0.020.040.060.08
Chloride (mmol)306090120
Acetate (mmol)306090120
  • Osmolality 2090 mOsm/kg (SmPC; same in the BPOM product information).
  • Composition from an Irish SmPC last revised April 2011 and Indonesian BPOM product information last revised September 2007; check against the current Philippine package insert.

Composition from the cited manufacturer SmPC (2011) and cross-checked against the Indonesian BPOM product information (2007): all values for the 1250, 1875 and 2500 ml bags agree. The 625 ml bag appears only in the SmPC (its values are exactly half of the 1250 ml bag).

Dose and rate limits

  • Adults: maximum infusion rate 1.7 ml/kg body weight per hour; maximum daily dose 35 ml/kg body weight (SmPC 4.2; same in the BPOM product information).

Kidney notes

  • Contraindicated in severe renal insufficiency, hyperkalemia, hypernatremia, disturbances of the electrolyte and fluid balance and states of hyperhydration (SmPC 4.3). Both the 2011 SmPC and the 2007 BPOM product information list severe renal insufficiency as a contraindication with no exception for patients on dialysis; check the current Philippine package insert for its wording.
  • Give with caution to patients with impaired cardiac or renal function; correct hyperkalemia and acidosis before starting; monitor serum electrolytes, water balance and acid-base balance (SmPC 4.4).

How it fits the ESPEN 2021 kidney nutrition guideline

  • ESPEN 2021 Recommendation 18 (Grade of recommendation 0 – Consensus (82.6% agreement)): protein intakes that may be prescribed are 0.6–0.8 g/kg body weight (BW)/d for a hospitalized patient with CKD without acute/critical illness; 1.2 g/kg BW/d with CKD and KF on conventional intermittent chronic KRT without acute/critical illness; 0.8–1.0 g/kg BW/d with AKI or AKI on CKD without acute/critical illness; start with 1 g/kg BW/day and gradually increase up to 1.3 g/kg BW/d if tolerated with acute/critical illness not on KRT; 1.3–1.5 g/kg/d for critically ill patients on conventional intermittent KRT; and 1.5 g/kg/d up to 1.7 g/kg/d for critically ill patients on continuous KRT (CKRT) or prolonged intermittent KRT (PIKRT). "If available, the pre-hospitalization body weight or usual body weight may be preferred over the ideal BW. Actual BW should not be considered for a protein prescription." (AKI, acute kidney injury.)
  • ESPEN 2021 Recommendation 25: "The choice of the most appropriate EN or PN formula should be made based on the calorie and protein ratio to provide the most accurate dosing in clinical practice." Grade of recommendation B – Strong consensus (91.3% agreement). (PN, parenteral nutrition.)
  • ESPEN 2021 Recommendation 24: "No disease-specific enteral nor parenteral formula oriented for patients with reduced kidney function should be routinely utilized in every patient with AKI, AKI on CKD, or CKD with KF in comparison to conventional formulas. Instead, their use is to be individualized (see recommendation 26)." Grade of recommendation B – Consensus (87.5% agreement).
  • ESPEN 2021 Recommendation 26: "In selected patients with electrolyte and fluid imbalances, concentrated “renal” EN or PN formulas with lower electrolyte content may be preferred over standard formulas." Grade of recommendation GPP – Strong consensus (95.7% agreement). (GPP, good practice point.)
  • ESPEN 2021 Recommendation 31: "Electrolytes abnormalities are common in patients with AKI, AKI on CKD, or CKD with KF receiving KRT and shall be closely monitored." Grade of recommendation A – Strong consensus (100% agreement).
  • ESPEN 2021 Recommendation 29: "Serum glucose levels shall be maintained between 140–180 mg/dl in hospitalized patients with AKI, AKI on CKD, or CKD with KF." Grade of recommendation A – Strong consensus (95.5% agreement). Recommendation 30: "Tight glucose control (80–110 mg/dl) shall not be pursued because of the increased risk of hypoglycemia." Grade of recommendation A – Strong consensus (100% agreement).
  • ESPEN 2021 Recommendation 14: "For patients undergoing KRT, the total energy provision by additional calories given in the form of citrate, lactate, and glucose from dialysis/hemofiltration solutions should be included in the calculations to determine the total daily energy provision to avoid overfeeding." Grade of recommendation B – Strong consensus (100% agreement). (KRT, kidney replacement therapy.)
  • ESPEN 2021 Recommendation 4: "Intradialytic parenteral nutrition (IDPN) shall be applied in malnourished non-critically ill hospitalized patients with CKD and KF on hemodialysis, or the same patients if at risk of malnutrition that fail to respond or do not tolerate ONS or EN." Grade of recommendation A – Strong consensus (91.7% agreement). (CKD, chronic kidney disease; KF, kidney failure; ONS, oral nutritional supplements; EN, enteral nutrition.)

Bottom line

A concentrated standard central bag that delivers more protein per ml, which can help when fluid must be limited, but it carries 47 mmol potassium and 20 mmol phosphate per 1250 ml. The available SmPC lists severe renal insufficiency as a contraindication without a dialysis exception: confirm the current Philippine insert before using it in kidney failure.

renalcarematters.com notes, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Check the current Philippine package insert before use. renalcarematters.com, reviewed

Kidney notes: Nutriflex Omega Peri

Nutriflex Omega Peri (B. Braun Melsungen AG) is a lower-osmolarity three-chamber bag of amino acids with electrolytes, glucose and a lipid emulsion containing medium-chain triglycerides, soybean oil and omega-3-acid triglycerides, for peripheral infusion. Philippine registrations: 1.25, 1.875 and 2.5 L bags. It is a standard formula containing potassium and phosphate.

Composition

Per presentation1250 ml bag1875 ml bag2500 ml bag
Amino acids (g)406080
Nitrogen (g)5.78.611.4
Lipid, total (g)5075100
Omega-3-acid triglycerides (g)57.510
Carbohydrate (glucose) (g)80120160
Energy, total (kcal)95514351910
Energy, non-protein (kcal)79511951590
Sodium (mmol)5075100
Potassium (mmol)304560
Magnesium (mmol)34.56
Calcium (mmol)34.56
Phosphate (mmol)7.511.2515
Zinc (mmol)0.030.0450.06
Chloride (mmol)487296
Acetate (mmol)406080
  • Theoretical osmolarity 840 mOsm/l; osmolality 950 mOsm/kg (SmPC).
  • Source is the Irish SmPC of the same B. Braun product sold in Ireland as Omeflex peri; its 1250 ml column (955 kcal, 40 g amino acids, 50 g lipid, 80 g carbohydrate) matches the Philippine registration exactly. Confirm against the Philippine package insert.

Composition from the cited manufacturer SmPC/package insert; values independently re-checked November 17, 2026.

Dose and rate limits

  • Adults: maximum daily dose 40 ml/kg body weight; maximum infusion rate 2.0 ml/kg/hour (SmPC 4.2).

Kidney notes

  • Contraindicated in "severe renal insufficiency in absence of renal replacement therapy" and in disturbances of the electrolyte and fluid balance (SmPC 4.3).
  • Give with caution to patients with impaired cardiac or renal function; experience in renal failure is limited (SmPC 4.4).
  • Use caution with drugs that raise serum potassium, such as ACE inhibitors, angiotensin receptor blockers and potassium-sparing diuretics (SmPC 4.5).
  • Refeeding may cause hypokalemia, hypophosphatemia and hypomagnesemia; close monitoring of serum electrolytes is required, with checks of water balance, acid-base balance and renal function (SmPC 4.4).

How it fits the ESPEN 2021 kidney nutrition guideline

  • ESPEN 2021 Recommendation 18 (Grade of recommendation 0 – Consensus (82.6% agreement)): protein intakes that may be prescribed are 0.6–0.8 g/kg body weight (BW)/d for a hospitalized patient with CKD without acute/critical illness; 1.2 g/kg BW/d with CKD and KF on conventional intermittent chronic KRT without acute/critical illness; 0.8–1.0 g/kg BW/d with AKI or AKI on CKD without acute/critical illness; start with 1 g/kg BW/day and gradually increase up to 1.3 g/kg BW/d if tolerated with acute/critical illness not on KRT; 1.3–1.5 g/kg/d for critically ill patients on conventional intermittent KRT; and 1.5 g/kg/d up to 1.7 g/kg/d for critically ill patients on continuous KRT (CKRT) or prolonged intermittent KRT (PIKRT). "If available, the pre-hospitalization body weight or usual body weight may be preferred over the ideal BW. Actual BW should not be considered for a protein prescription." (AKI, acute kidney injury.)
  • ESPEN 2021 Recommendation 25: "The choice of the most appropriate EN or PN formula should be made based on the calorie and protein ratio to provide the most accurate dosing in clinical practice." Grade of recommendation B – Strong consensus (91.3% agreement). (PN, parenteral nutrition.)
  • ESPEN 2021 Recommendation 24: "No disease-specific enteral nor parenteral formula oriented for patients with reduced kidney function should be routinely utilized in every patient with AKI, AKI on CKD, or CKD with KF in comparison to conventional formulas. Instead, their use is to be individualized (see recommendation 26)." Grade of recommendation B – Consensus (87.5% agreement).
  • ESPEN 2021 Recommendation 26: "In selected patients with electrolyte and fluid imbalances, concentrated “renal” EN or PN formulas with lower electrolyte content may be preferred over standard formulas." Grade of recommendation GPP – Strong consensus (95.7% agreement). (GPP, good practice point.)
  • ESPEN 2021 Recommendation 31: "Electrolytes abnormalities are common in patients with AKI, AKI on CKD, or CKD with KF receiving KRT and shall be closely monitored." Grade of recommendation A – Strong consensus (100% agreement).
  • ESPEN 2021 Recommendation 29: "Serum glucose levels shall be maintained between 140–180 mg/dl in hospitalized patients with AKI, AKI on CKD, or CKD with KF." Grade of recommendation A – Strong consensus (95.5% agreement). Recommendation 30: "Tight glucose control (80–110 mg/dl) shall not be pursued because of the increased risk of hypoglycemia." Grade of recommendation A – Strong consensus (100% agreement).
  • ESPEN 2021 Recommendation 14: "For patients undergoing KRT, the total energy provision by additional calories given in the form of citrate, lactate, and glucose from dialysis/hemofiltration solutions should be included in the calculations to determine the total daily energy provision to avoid overfeeding." Grade of recommendation B – Strong consensus (100% agreement). (KRT, kidney replacement therapy.)
  • ESPEN 2021 Recommendation 4: "Intradialytic parenteral nutrition (IDPN) shall be applied in malnourished non-critically ill hospitalized patients with CKD and KF on hemodialysis, or the same patients if at risk of malnutrition that fail to respond or do not tolerate ONS or EN." Grade of recommendation A – Strong consensus (91.7% agreement). (CKD, chronic kidney disease; KF, kidney failure; ONS, oral nutritional supplements; EN, enteral nutrition.)
  • ESPEN 2021 Recommendation 27: "There is not enough evidence to support the routine use of omega-3 polyunsaturated fatty acids (PUFA) supplements or PN solutions enriched with omega-3 PUFA in hospitalized patients with AKI, AKI on CKD or CKD with KF." Grade of recommendation GPP – Strong consensus (95.8% agreement).

Bottom line

A standard peripheral bag with an omega-3-containing lipid; ESPEN finds the evidence insufficient to use omega-3-enriched PN routinely in kidney disease. In severe renal insufficiency it needs renal replacement therapy; count its potassium and phosphate, and watch potassium closely with RAAS blockers.

renalcarematters.com notes, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Check the current Philippine package insert before use. renalcarematters.com, reviewed

Dosage forms

Philippines

  • Emulsion for intravenous infusion
  • Emulsion for injection for i.v. infusion: 40 g, Lipid 50 g, Carbohydrate 80 g

Registered products in the Philippines

3 products registered with the Food and Drug Administration (FDA) Philippines list Amino acids + Glucose + Lipids as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products3
Philippine FDA-registered products for Amino acids + Glucose + Lipids
Package insert
Nutriflex Lipid PeriGlucose + Amino Acids + Lipids
Emulsion for Intravenous InfusionThree-chamber plastic x 1250 mL, 1875 mL and 2500 mL
Rx
B. Braun Melsungen AGGermany
Importer: B. Braun Medical Supplies, Incorporated
DR-XY29310
Jan 21, 2029
Nutriflex Lipid SpecialGlucose + Amino Acids + Lipids
Emulsion for Intravenous InfusionThree-chamber plastic x 625 mL, 1250 mL, 1875 mL, and 2500 mL
Rx
B. Braun Melsungen AGGermany
Importer: B. Braun Medical Supplies, Incorporated
DR-XY29311
Jan 21, 2029
Nutriflex Omega PeriGlucose + Lipids + Amino Acids
955 kcal, Amino acid 40 g, Lipid 50 g, Carbohydrate 80 g Emulsion for Injection for I.V. InfusionThree-Chamber Plastic Bag Made of a Transparent, Colorless Multi-Layer Polymer Film x 1.25 L, 1.875 L and 2.5 L (Bag of 1's & Box of 5's)
Rx
B. Braun Melsungen AGGermany
B. Braun Medical Supplies, Incorporated
DR-XY49834
Nov 5, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  2. B. Braun. (2019). NuTRIflex Lipid peri emulsion for infusion (PA0736/013/001) [Summary of product characteristics; text revised August 2019]. Health Products Regulatory Authority. https://assets.hpra.ie/products/Human/20603/Licence_PA0736-013-001_27082019114211.pdf
  3. Fiaccadori, E., Sabatino, A., Barazzoni, R., Carrero, J. J., Cupisti, A., De Waele, E., Jonckheer, J., Singer, P., & Cuerda, C. (2021). ESPEN guideline on clinical nutrition in hospitalized patients with acute or chronic kidney disease. Clinical Nutrition, 40(4), 1644–1668. https://doi.org/10.1016/j.clnu.2021.01.028
  4. B. Braun. (2011). NuTRIflex Lipid special emulsion for infusion (PA 736/15/1) [Summary of product characteristics; text revised April 2011]. Health Products Regulatory Authority. https://assets.hpra.ie/products/Human/20605/LicenseSPC_PA0736-015-001_06052011115043.pdf
  5. B. Braun Melsungen AG. (2007). Nutriflex Lipid special emulsion for infusion [Product information; date of last revision September 2007]. Badan Pengawas Obat dan Makanan (Indonesian Food and Drug Authority). https://registrasiobat.pom.go.id/files/assesment-reports/obat_baru/Nutriflex%20Lipid%20Special.pdf https://registrasiobat.pom.go.id/files/assesment-reports/obat_baru/Nutriflex%20Lipid%20Special.pdf
  6. B. Braun. (2026). Omeflex peri emulsion for infusion (PA0736/033/002) [Summary of product characteristics; text revised April 2026]. Health Products Regulatory Authority. https://assets.hpra.ie/products/Human/20636/Licence_PA0736-033-002_16042026132947.pdf

renalcarematters.com content: Parenteral nutrition kidney notes (Nutriflex Lipid Peri): reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Parenteral nutrition kidney notes (Nutriflex Lipid Special): reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Parenteral nutrition kidney notes (Nutriflex Omega Peri): reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .